Tecovirimat (TPOXX) for Treatment of Mpox

Evidence-based interventions are needed to respond to current and future mpox outbreaks within and beyond the United States. To help meet domestic and international mpox response goals, CDC is urging clinicians to let patients with mpox know that oral tecovirimat is available through STOMP and encourage them to enroll. Providers should inform patients about STOMP so they can consider enrolling in the study. However, enrollment in the study is voluntary, and patients who decline to take part, or who do not meet the criteria to participate, can still obtain tecovirimat if recommended. For more information about obtaining TPOXX or about the STOMP study, visit www.cdc.gov/poxvirus/mpox/clinicians/obtaining-tecovirimat.html or https://www.stomptpoxx.org/main.   

TPOXX may still be prescribed on a case-by-case basis through a special CDC process. It is not FDA-approved specifically for mpox, and it does not have an Emergency Use Authorization (EUA) for mpox currently. 

For its investigational use, visit the CDC: https://www.cdc.gov/mpox/hcp/clinical-care/tecovirimat.html